Nurse Mates Partnership

ANDOVER, Mass. (PRWEB)
June 20, 2023

For the second year in a row, Nurse Mates is proud to partner with Stanford University medical student, advocate, and founder of Dysunderstood, Ella Eastin. A record-breaking swimmer on the path to qualifying for the U.S. Olympic Swim Team, Ella was diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and dysautonomia, debilitating illnesses that ended her swimming career and set her life on an inspiring new course.

Now studying to be a physician, Ella is dedicated to helping others suffering from ME/ CFS and autonomic nervous system disorders (known as dysautonomia) and is the founder of Dysunderstood.com, an online forum for people living with the challenges of these chronic, often “invisible” illnesses, where she shares her own experiences. She also motivates and encourages young competitive swimmers through her work as a keynote speaker and mentor.

“Ella’s resilience and perseverance in turning a heartbreaking setback and life-changing diagnosis into an opportunity to help others through her medical career and unique online support community are inspirational,” says Lynne Dejadon, Vice President of Nurse Mates. “We’re excited to partner with her again this year to help spread the word about Dysunderstood and its mission.”

As part of this year’s collaboration, Ella has selected her top on-the-job favorites from the Nurse Mates footwear and accessory collection she recommends for her fellow medical students, doctors, and nurses.

To shop her picks and learn more about Ella Eastin and Dysunderstood, please visit https://www.nursemates.com/en/ella-eastin.html.

Share article on social media or email:

Surgeon’s Advisor Partners with Semrush

By partnering with Semrush, we’re further strengthening our ability to provide top-tier digital marketing solutions; the tools and resources available through this partnership will enable us to better serve our clients, optimizing their online presence & effectively reaching their target audiences.

MIAMI (PRWEB)
June 20, 2023

Surgeon’s Advisor, a premier digital marketing agency specialized in enhancing the online presence of medical practices, is proud to announce their new partnership with Semrush, becoming a Certified Agency Partner. This strategic alliance promises to provide enhanced value and innovative digital marketing solutions to Surgeon’s Advisor’s clients.

The partnership with Semrush, a leading provider of competitive research services for online marketing, gives Surgeon’s Advisor access to a comprehensive suite of tools that will bolster their already robust digital marketing offerings. As a Certified Agency Partner, Surgeon’s Advisor will leverage Semrush’s resources, including superior analytics and insights, to deliver even more effective and results-oriented strategies to their clients.

“By partnering with Semrush, we’re further strengthening our ability to provide top-tier digital marketing solutions,” said Robert Baxter, CEO of Surgeon’s Advisor. “The tools and resources available through this partnership will enable us to better serve our clients, optimizing their online presence and effectively reaching their target audiences.”

About Surgeon’s Advisor

​​Surgeon’s Advisor is a distinguished digital marketing agency, dedicated to propelling medical practices into the digital forefront by augmenting their online prominence and expanding their potential patient reach. With a tailored approach, Surgeon’s Advisor delivers an array of services, including Search Engine Optimization (SEO), Pay-Per-Click (PPC) advertising, social media marketing, website design, and reputation management, all custom-designed to cater to the specific demands of the healthcare sector.

What truly distinguishes Surgeon’s Advisor from other digital agencies is their deep-seated understanding of the medical industry, combined with their commitment to personalized, results-driven strategies. They work alongside clients to navigate the complexities of the digital landscape. By delivering measurable outcomes, Surgeon’s Advisor ensures that their services not only meet but exceed the expectations of their clients, providing unmatched value in the realm of healthcare digital marketing.

Surgeon’s Advisor Digital Marketing Services

As a leading digital marketing agency focused on the medical sector, Surgeon’s Advisor offers an extensive array of services designed to amplify the online visibility of medical practices. Each service is meticulously tailored to align with the specific needs of the healthcare industry, thereby fostering growth and innovation for medical practices in the digital landscape.

At the core of their service portfolio is SEO. Surgeon’s Advisor utilizes advanced, data-informed strategies to enhance the search engine rankings of their clients. Through a combination of keyword research, website optimization, and high-quality content creation, Surgeon’s Advisor ensures that medical practices are not just found, but prominently featured in online search results. Their SEO strategies are continuously refined and updated to keep pace with the dynamic nature of search engine algorithms, guaranteeing sustainable online visibility for their clients.

Pay-Per-Click (PPC) advertising is another integral service offered by Surgeon’s Advisor. By creating targeted and compelling advertising campaigns, Surgeon’s Advisor helps medical practices reach potential patients who are actively searching for medical services. The PPC strategies employed by Surgeon’s Advisor are designed for maximum ROI, ensuring that each advertising dollar is optimally spent.

Social Media Marketing is another key pillar of Surgeon’s Advisor’s digital marketing offerings. In today’s interconnected world, a robust social media presence is indispensable for any business, and medical practices are no exception. Surgeon’s Advisor crafts engaging and shareable content, manages social media profiles, and interacts with users to build a strong, positive online image for their clients.

Website design, a crucial element of any digital marketing strategy, is another area where Surgeon’s Advisor excels. Recognizing that a website serves as the digital storefront for a medical practice, Surgeon’s Advisor creates sites that are visually appealing, user-friendly, and optimized for conversions. They ensure that each website is reflective of the practice’s brand image and resonates with its target audience.

Reputation management is another pivotal service provided by Surgeon’s Advisor. They understand that in the digital age, a practice’s online reputation can significantly impact its success. As such, they help clients manage and enhance their online reputation by addressing negative reviews promptly and effectively, while also highlighting positive patient experiences.

Furthermore, as a Certified Agency Partner of Semrush, Surgeon’s Advisor now has access to an even more extensive suite of tools and analytics to bolster these services. This partnership signifies an enhanced capability to understand their clients’ online presence, competition, and the latest trends in digital marketing, enabling the creation of even more effective, results-oriented strategies.

Contact the Agency

For medical practices looking to enhance their online visibility, engage more effectively with potential patients, and navigate the complex digital landscape, Surgeon’s Advisor offers the expertise and innovative solutions needed to achieve online marketing success.

Contact Surgeon’s Advisor to learn more about the benefits of their new partnership with Semrush and how they can transform your digital marketing strategy.

Share article on social media or email:

Abstrax Helps BHO Extraction Remain Legal in Canada

“…we dove into meticulous research and evidence-based arguments to help the legislature understand the reality of the (BHO Extraction) situation, while driving home the plethora of health and wellness benefits that come with the process.” – Kevin Koby, CSO of ABSTRAX

TUSTIN, Calif. (PRWEB)
June 20, 2023

ABSTRAX, an industry leader in the study and production of cannabis and botanically-derived terpenes, has officially released a white paper detailing the company’s role in 2017 in preventing the prohibition of hydrocarbon extraction (including BHO extraction) in Canada.

To accomplish this, Kevin Koby, Chief Science Officer (CSO) and Co-Founder of ABSTRAX, and his team, alongside industry partners ETS and Hollistek, presented a compelling case that emphasizes the necessity for regulatory oversight while addressing concerns regarding illicit production and the safety of producers and consumers.

The BHO (Butane Hash Oil) extraction method has been often targeted by legislators as being dangerous due to risks associated with handling flammable and volatile substances such as butane gas. Without proper oversight and training, extractors can be exposed to dangerous contaminants within poorly ventilated rooms and be injured due to uncontrolled pressure during the process.

“While there are inherent dangers involved, BHO will never go away,” said Koby. “In fact, if made illegal extractors will continue to use the method and skirt safety practices. Knowing this, we dove into meticulous research and evidence-based arguments to help the legislature understand the reality of the situation, while driving home the plethora of health and wellness benefits that come with the process.”

Hydrocarbon extraction allows producers to capture and preserve the full spectrum of cannabinoids and terpenes found in cannabis, resulting in extracts that offer enhanced potency and flavor profiles. Health benefits of concentrated cannabis extracts are used for pain management, anxiety and stress relief, appetite stimulation – and are even thought to have important neuroprotective properties.

To chronicle this important milestone in ABSTRAX’s history and the research that led Canadian legislators to choose regulation over banning BHO extraction, ABSTRAX has released a whitepaper that can be accessed at the following link: https://abstraxtech.com/pages/terpene-research.

“ABSTRAX remains committed to driving innovation and advancing the cannabis industry through its relentless pursuit of excellence in extraction, formulation, and research,” said Koby. “By taking the lead in educating the Canadian government and advocating for the continued legality and regulation of hydrocarbon extraction, we’re showcasing our dedication to fostering a safe, transparent, and thriving cannabis market.”

About ABSTRAX

Leveraging its proven background in cannabis research, ABSTRAX is the leader in the research, development, and production of botanically-derived and cannabis-inspired terpenes that create unforgettable sensorial experiences. Headquartered in California, the company owns and operates a state-of-the-art type 7 licensed research and manufacturing lab where it’s award-winning product developers and scientists leverage the most advanced strain analysis technology to extract and study aroma compounds via three-dimensional analysis, allowing for each and every compound within a plant to be named and studied. The company has partnered with many of the best cultivators in the industry to study their cannabis profiles and create the world’s most advanced terpene formulations. As a result of its efforts, ABSTRAX offers the largest terpene catalog of the most popular strains – botanically-derived terpene blends and isolates native to cannabis. These ingredients, also known as functional flavors and aromas, are used in vapes, concentrates, edibles, beer, essential oils, fragrances, cosmetics, topicals, tinctures, alcohol, food and beverage, personal care, and more. The company works with internationally recognized brands and provides unparalleled cannabis research, innovation, and custom formulations to create products that engage and thrill consumers. ABSTRAX also devotes significant resources to developing the highest terpene standards and best practices in the industry. The company has developed a robust quality management system including Gas Chromatography analysis and molecular distillation of natural ingredients to achieve the highest purity standards. Investigating and ensuring that ingredients used in its own products, and products within its industry, are safe for consumption. The terpene industry is a rapidly growing segment of the global flavor and fragrance market, which is expected to grow to $35 billion by 2024. This market segment includes the cannabis, CBD, skincare, cosmetics, health and wellness, food and beverage industries. For more information, visit AbstraxTech.com.

Share article on social media or email:

“This patent validates the revolutionary nature of the product development efforts at Curio and the novel application of our pulse-release technology.” – Dr. Edward Rudnic, Chairman of Curio’s Scientific Board and Chief Scientific Officer.

TIMONIUM, Md. (PRWEB)
June 20, 2023

Curio Wellness, a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products derived from cannabis, was awarded a Utility patent for Good Night™ by Curio, marking a significant milestone for the company and brand.

Good Night™, Maryland’s only pulse-release cannabis sleep aid line has led the market since its release in 2021. The ratio tablet is designed to help consumers fall asleep faster, stay asleep longer and reduce morning grogginess.

Curio Wellness was granted US Patent (11,654,130) on May 23, 2023 which will be in force until January 2042. Good Night’s patented technology secures a unique, pulse-delivery system for medicinal cannabis sleep products, demonstrating Curio’s adherence to driving innovation, breaking boundaries and improving patient outcomes and the overall experience for cannabis-derived medicine.

“This patent validates the revolutionary nature of the product development efforts at Curio and the novel application of our pulse-release technology,” added Dr. Edward Rudnic, Chairman of Curio’s Scientific Board and its Chief Scientific Officer. “This is the first of many condition-specific product patents we anticipate to issue over the coming years thanks to the continued innovation and unmatched clinical testing executed by Curio’s product innovation team.”

The proprietary pulse-release doses in two stages for sustained release and has been scientifically proven to improve sleep quality. An independent study, published in the American Journal of Endocannabinoid Medicine, found that participants woke up less frequently and spent less time awake at night. Additionally, 65 percent of participants reported feeling more satisfied with their sleep and feeling better rested during the day four times per week, double the rate found before the trial.

“Curio’s medical-based research methods are the foundation of all the innovative work we have accomplished thus far,” said Michael Bronfein, CEO of Curio Wellness and co-inventor. “This patent is a significant and exciting milestone for Curio, and solidifies our commitment to developing cutting-edge cannabis products that enable our patients to enjoy a better quality of life.”

Curio Wellness is the leading developer of cannabis-derived medical products in Maryland. In addition to cannabis sleep aids, in 2022 Curio launched GI by Curio™ targeting gastrointestinal health issues as well as Move by Curio™ targeting muscle and joint pain. Earlier this year, it launched Good Day™ targeting anti-anxiety and stress relief. Curio Wellness is Maryland’s first cGMP-certified manufacturer, which means that its products meet the same quality and safety standards required by the FDA and those produced by the world’s leading pharmaceutical companies.

About Curio Wellness

Founded in 2014 in Baltimore, Maryland, Curio Wellness is a cGMP-certified, vertically integrated cannabis company and trusted healthcare partner. Recognized as the leading wellness brand in cannabis by BDS Analytics, Curio is committed to serving patients with safe, effective, and reliable cannabis-based medicine. For more information, visit https://curiowellness.com.

Share article on social media or email:

Manufactured to OEM specifications, Meller Custom Sapphire Optics can meet ±0.002” tolerances on special features, depending upon configuration.

Meller custom sapphire optics can include polished radii to prevent stress, chipping, and cracking along with bevels, chamfers, flats, grooves, holes, radii, steps, and wedges to 6.5º ±1 min.

PROVIDENCE, R.I. (PRWEB)
June 20, 2023

Meller Optics, Inc. has introduced custom fabricated sapphire lenses, windows, and domes that can incorporate bevels, chamfers, flats, grooves, holes, radii, steps, wedges, and multiple features.

Meller Custom Sapphire Optics are ideal for applications requiring a robust lens, window, or dome that transmits from the UV to IR (270 nm to 4.7 µm). Featuring Mohs 9 hardness which is second only to diamond, they can include polished radii to prevent stress, chipping, and cracking along with bevels, chamfers, flats, grooves, holes, radii, steps, and wedges to 6.5º ±1 min.

Manufactured to OEM specifications, Meller Custom Sapphire Optics can meet ±0.002” tolerances on special features, depending upon configuration and major surfaces can be polished to 10-5 scratch-dig. Roughness can be ≤0.3 rm RA, and flatness can be held to 0.5 fringes HeNe. Applications include UAVs, UUVs, drones, aerospace, military, and machine inspection.

Meller Custom Sapphire Optics are priced according to configuration and quantity. Price quotations are available upon request.

For more information contact:

Meller Optics, Inc.

Craig Schweriner, Marketing

120 Corliss St. / P.O. Box 6001

Providence, RI 02940

(800) 821-0180 FAX (401) 331-0519

e-mail: craig@melleroptics.com

http://www.melleroptics.com

Share article on social media or email:

“Alzheimer’s research is at a pivotal point,” said Dr. Jeffrey Cummings, Director at the Chambers-Grundy Center for Transformative Neuroscience.

TORONTO (PRWEB)
June 20, 2023

The Global Alzheimer’s Platform Foundation (GAP) is delighted to announce a collaborative, free webinar focusing on the current state of Alzheimer’s research and the innovative use of biomarkers in drug development. The event will delve into the latest advances, discussing the potential of blood-based and digital biomarkers in identifying key hallmarks of Alzheimer’s disease.

A disease that sees over 1,000 new diagnoses each day, Alzheimer’s research is in a race against time. In an effort to hasten this crucial research, GAP conducted its inaugural study, Bio-Hermes. This groundbreaking study evaluated the ability of promising biomarkers to reflect brain amyloid PET scans in participants, with a significant number of enrollees from racial and ethnic minority populations. This critical exploration into the correlation between diagnostic technologies and disease indicators is a stride toward more precise and inclusive diagnoses.

However, the sheer volume of data generated from such studies necessitates meticulous analysis. Pentara Corporation, a leader in data analysis, will discuss the importance of quality data, providing insights into how the Bio-Hermes data is positioned in this competitive environment.

“Alzheimer’s research is at a pivotal point,” said Dr. Jeffrey Cummings, Director at the Chambers-Grundy Center for Transformative Neuroscience. “The findings from the Bio-Hermes study have the potential to influence our understanding of the disease and how we approach its diagnosis and treatment.”

Join renowned speakers as they review the findings from the Bio-Hermes study and discuss the implications for Alzheimer’s research. The webinar aims to provide attendees with a deeper understanding of the advances in the most common blood and digital biomarkers for Alzheimer’s disease trials, the statistical relationship between individual biomarkers and the association between blood-based biomarkers and amyloid PET scans.

“Our mission at GAP is to accelerate the delivery of innovative therapies to those living with Alzheimer’s. This webinar is a step in that direction, and we’re excited to share our insights with the community,” said John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation.

Join Dr. Jeffrey Cummings, Director, Chambers-Grundy Center for Transformative Neuroscience, UNLV; Dr. Richard Mohs, Chief Scientific Officer, Global Alzheimer’s Platform Foundation; Dr. Suzanne Hendrix, CEO, Pentara Corporation; and John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation, for the live webinar on Monday, July 10, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Alzheimer’s and Biomarkers in Drug Development: The ABCD’s of Clinical Trial Innovation.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

“Mindpeak’s IHC quantification algorithms are already helping pathologists make faster, more informed decisions to advance the quest for precision medicine. We’re looking forward to incorporating them into our ecosystem.” – Stephan Fromme, Head of Strategic Alliances, Proscia

HAMBURG, Germany and PHILADELPHIA (PRWEB)
June 20, 2023

Mindpeak, a leading provider of artificial intelligence (AI) for pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have announced a partnership to broaden access to improved diagnosis for cancer patients. Through the collaboration, the companies lay the foundation for delivering tightly integrated AI-powered workflows that enable pathologists to provide more efficient, informed, and reproducible clinical decisions.

Up to 70% of clinical decisions depend on pathology.[1] Laboratories are increasingly adopting digital pathology, which shifts the standard of diagnosis from microscope to whole slide image, to meet growing expectations for precision medicine. In doing so, they can leverage AI to unlock new insights that empower pathologists in making a diagnosis as well as drive efficiency and quality gains.

The newly announced partnership paves the way for delivering an integrated solution that brings together Mindpeak’s CE-IVD algorithms for immunohistochemistry (IHC) quantification* with Proscia’s CE-IVDR Concentriq® Dx** software platform. Mindpeak’s AI solutions automatically detect and measure the presence of biomarkers including HER2, Ki-67, and ER/PR for breast cancer and PD-L1 for lung cancer. More algorithms will be introduced soon. Their algorithm for detecting Ki-67 for breast cancer has been proven to identify more patients eligible for treatment while saving 80-90% in diagnostic time[2] and their HER2 algorithm just outperformed the competition[3] in HER2low scoring in accuracy and usability.

“Mindpeak is delivering fast and reliable tools to solve pathology’s biggest challenges, and we are excited to expand their reach through this partnership,” says Founder and CEO Felix Faber. “Leading laboratories rely on Proscia’s Concentriq Dx because it offers the robust functionality needed to achieve fully digital diagnosis and is designed to seamlessly incorporate state-of-the-art AI into day-to-day operations. Our integrated solution will enable us to assist a larger number of pathologists and improve outcomes for even more patients.”

Concentriq Dx is a modern digital pathology platform that drives primary diagnostic workflows for reference laboratories, hospitals, and health systems of all sizes. It offers a compelling user experience that allows pathologists to quickly transition away from the microscope and work with speed and ease. An open platform, Concentriq Dx is designed to integrate AI applications from Proscia, Proscia’s customers, and leading third parties, including Mindpeak, into routine workflows so that laboratories can realize the full promise of pathology’s computational future at scale.

“Proscia has pioneered an open approach to digital pathology because we believe it is the only way that laboratories can drive a complete transformation of their practice,” says Stephan Fromme, Proscia’s Head of Strategic Alliances. “Mindpeak’s IHC quantification algorithms are already helping pathologists to make faster, more informed decisions in clinical routine in the USA and EU to advance the quest for precision medicine. We are looking forward to incorporating them into our ecosystem through this partnership.”

*In the EU, Mindpeak’s CE-marked AI algorithms are fully compliant to IVDR for clinical routine. In the USA, they are for research use only, not for use in diagnostic procedures.

**Concentriq Dx is CE-marked under IVDR.

About Mindpeak

Mindpeak is Europe’s Leader for AI-software for pathology. Over 17,000 patients have been diagnosed with the help of Mindpeak’s AI. With a focus on tissue biomarker analysis and discovery, Mindpeak serves clinical labs and biopharma companies around the globe. Mindpeak’s algorithms were the first AI in digital pathology to be used in routine clinical diagnostics in the USA and EU.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf

[2] Colón, E. et al. (2023) AI in combination with the global counting methodology by the International Ki67 in Breast Cancer Working Group identifies more patients eligible for treatment and increases diagnostic speed by 5x-8x. Presented at USCAP 20s23. https://bit.ly/43ohY3u

[3] Mindpeak comes out on Top in a comparative Study on HER2low scoring by Cypath and Institut Gustave Roussy. https://lnkd.in/eYuY6R3m

Share article on social media or email: